BioSpace News Archive

Merck is buying all outstanding shares of Peloton, a clinical-stage oncology company, for an upfront payment of $1.05 billion in cash. Peloton will also be eligible for another $1.15 billion based on various regulatory and sales milestones.

The FDA approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) as the first treatments for transthyretin-meditated amyloidosis.

Germany-based Boehringer Ingelheim announced that its SENSCIS Phase III clinical trial met its primary endpoint, which was reduction in the annual rate of decline in forced vital capacity.

Despite hitting endpoints in the late-stage trial, BioCryst’s BCX7353 results do not stack up against Takeda’s Takhzyro, which was approved last year.

“We’re investing in what companies will be doing in the future,” Burns said of the company’s focus on developing new treatment approaches.

Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”) based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years.

Breakthrough in industrial large-scale manufacturing of well-defined biomedical fiber-based scaffolds for a wide variety of medical applications

Heidelberg Pharma AG announced that the shareholders of the Company approved the resolutions of the administration with large majorities during the Annual General Meeting.

Joins MD Anderson from University Health Network/Princess Margaret Cancer Centre

Horus Pharma, an independent laboratory specialized in ophthalmology, announces that it is now making ILUVIEN® available to French patients. ILUVIEN is owned by Alimera Sciences, Inc. (US).